Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 for HER2-positive Solid Tumors

NCT04684459 is registered in ClinicalTrials.gov with Sichuan University as lead sponsor.

NCT NCT04684459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04684459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 for HER2-positive Solid Tumors
Lead sponsor
Sichuan University
Phase
Phase 1
Overall status
Recruiting
Start date
March 12, 2021
Completion date
December 30, 2025
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive malignancies, peritoneal carcinoma metastatic, pleural effusion, malignant